| 摘要: |
| ［摘要］ 目的 探讨孟鲁司特治疗IgA血管炎患儿的临床疗效及其对免疫功能的影响。方法 选择2018-06～2019-06该院儿科收治的80例IgA血管炎患儿为研究对象，按照随机数字表法将其分为观察组（n=40）和对照组（n=40）。对照组予以常规综合治疗，观察组在对照组治疗基础上加用孟鲁司特治疗；比较两组的临床疗效、临床症状消失时间及免疫功能指标。结果 （1）观察组总有效率为95.00%，显著高于对照组的77.50%（P<0.05）。（2）观察组各临床症状消失时间均明显短于对照组（P<0.05）。（3）治疗前，两组各免疫功能指标比较差异均无统计学意义（P>0.05）。治疗后，两组CD4+、CD4+/CD8+水平均明显升高，CD8+水平明显下降，且观察组各免疫功能指标改善情况明显优于对照组（P<0.05），而CD3+水平无明显改变（P>0.05）。结论 孟鲁司特治疗IgA血管炎患儿疗效确切，可有效缓解临床症状，改善免疫功能，值得在临床上推广应用。 |
| 关键词: 孟鲁司特 IgA血管炎 临床疗效 免疫功能 |
| DOI：10.3969/j.issn.1674-3806.2020.06.20 |
| 分类号:R 725.4 |
| 基金项目: |
|
| Clinical effect of montelukast on IgA vasculitis in children and analysis of its effect on immune function |
|
ZHAO Xin, DONG De-xing
|
|
Department of Pediatrics, Huazhong University of Science and Technology Union Shenzhen Hospital, Guangdong 518000, China
|
| Abstract: |
| ［Abstract］ Objective To investigate the clinical effect of montelukast on immunoglobulin A(IgA) vasculitis in children and its effect on immune function. Methods Eighty children with IgA vasculitis admitted to the pediatric department of our hospital from June 2018 to June 2019 were selected as the research subjects and were divided into observation group(n=40) and control group(n=40) according to the random number table method. The control group received routine comprehensive treatment, and the observation group received the same treatment as the control group plus montelukast. The clinical efficacy, the time of clinical symptom disappearance and the changes of immune function indexes were compared between the two groups. Results (1)The total effective rate of the observation group(95.00%) was significantly higher than that of the control group(77.50%)(P<0.05). (2)The time of clinical symptom disappearance in the observation group was significantly shorter than that in the control group(P<0.05). (3)Before treatment, there was no significant difference in each immune function index between the two groups(P>0.05). Compared with those before treatment, the levels of CD4+ and CD4+/CD8+ were significantly increased and the level of CD8+ was significantly decreased in the observation group and the control group after treatment, and the improvement of immune function indexes except CD3+ in the observation group was significantly better than that in the control group(P<0.05). Conclusion Montelukast is effective in treatment of IgA vasculitis in children. It can effectively relieve the clinical symptoms and improve the immune function, and is worthy of clinical application. |
| Key words: Montelukast Immunoglobulin A(IgA) vasculitis Clinical efficacy Immune function |
